Trial Profile

A Phase 1 multiple ascending dose study of PRX-012 in Alzheimer's disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PRX-012 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Acronyms ASCENT-2
Sponsors Prothena

Most Recent Events

16 Jun 2025 According to a Prothena media release, Company expects initial data in August from Phase 1 ASCENT clinical trials of its wholly owned PRX012 program in Alzheimer's disease.
12 Nov 2024 According to a Prothena media release, Poster presentation at CTAD 2024 highlighted the clinical trial design and patient demographic diversity of the ongoing ASCENT clinical trials.
12 Nov 2024 According to a Prothena media release, company expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com